Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.3 USD | -0.43% | +2.14% | -4.77% |
May. 03 | Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate | MT |
May. 03 | J&J: to present advances in retinal diseases | CF |
Official Publications
1st-half-year results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-1 | CO | |
Minutes of the general assembly | CO | |
SEC Filing 8K | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
Proxy Statments | CO | |
SEC Filing 10K | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
Dividends | CO | |
Acquisition | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
SEC Filing 8K | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-2 | CO | |
Slide show half-year results | CO |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Official Publications